MediWound
Focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 9 % | 12 % | (29 %) | 8 % | 18 % | 26 % | 18 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (42 %) | (24 %) | (68 %) | (85 %) | (96 %) | (86 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (57 %) | (74 %) | (36 %) | (149 %) | (90 %) | (94 %) | (74 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 43 % | 38 % | 40 % | 44 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
MediWound is a biopharmaceutical company specializing in innovative solutions for burn wound care. The company focuses on developing and commercializing products for the removal of eschar, which is dead tissue that needs to be removed to promote healing in burn wounds. MediWound's core product, approved by the European Medicines Agency (EMA) in December 2012, targets adults with deep partial and full thickness thermal burns. The company operates a cGMP (current Good Manufacturing Practice) manufacturing facility that produces sterile pharmaceutical products, ensuring high-quality standards are met.
MediWound serves healthcare professionals and patients, primarily in the European market, but aims to expand globally. The business model revolves around the development, approval, and commercialization of its innovative drug products. Revenue is generated through the sale of these pharmaceutical products to hospitals and healthcare providers.
Keywords: biopharmaceutical, burn care, eschar removal, thermal burns, cGMP manufacturing, sterile pharmaceuticals, healthcare professionals, European market, innovative drug, wound healing.